DC521022

DC521022 is an orally bioavailable small molecule selective sphingosine-1-phosphate receptor 1 (S1P1) agonist developed by the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences. It is currently in Phase II clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS). The drug's mechanism of action involves binding to S1P1 receptors on the surface of lymphocytes, which triggers receptor internalization and degradation. This process sequesters lymphocytes within the lymph nodes, preventing their egress into the peripheral blood and subsequent migration into the central nervous system. By reducing the infiltration of inflammatory cells into the brain and spinal cord, DC521022 aims to mitigate the neuroinflammation and axonal damage characteristic of multiple sclerosis.